Search Results for "Rituximab Patent"

13:21 EST 25th November 2015 | BioPortfolio

Matching Channels

CD20 Antibodies

The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bl...

Biosuperior Antibodies

After biosimilar versions of therapeutic proteins have become reality in Europe and in the US, now it’s the turn of therapeutic antibodies to be in the line of fire. Patents of the first wave of...


India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

Tumor Necrosis Factor TNF Products

Tumor Necrosis Factor (TNF) and TNF receptor antagonists and agonists used to treat TNF-mediated inflammatory diseases such as rheumatoid arthritis or to treat cancer. TNF blockers are the commerc...

Matching News

Celltrion files IPR against Genentech

Celltrion Inc. (KOSDAQ:068270) filed an inter partes review (IPR) petition with the U.S. Patent and Trademark Office challenging a patent from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) t...

Rituximab Retreatment after Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients with Low-Tumor Burden Follicular Lymphoma

In a randomized clinical trial, patients with low–tumor burden follicular lymphoma whose cancer responded to initial treatment with rituximab (Rituxan®) experienced similar disease control regardle...

Complement 3b Deposition on Rituximab Opsonized

The ImageStream® imaging flow cytometry platform was used to study the mechanism of action of Rituximab (RTX). RTX is a therapeutic monoclonal antibody directed against CD20 for the treatment o...

Our £60,000 rituximab fund is still available to be put towards a full-scale clinical trial | 12 September 2015

Øystein Fluge and Olav Mella – they're running the rituximab trials in Norway.

Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study

Further evidence of Rituximab’s effectiveness in treating ME/CFS | PlosOne publish results of Phase 2 trial | 1 July 2015

Øystein Fluge and Olav Mella – they're leading the Rituximab trials in Norway.

Pivotal clinical trials for rituximab biosimilars

Biosimilars of Roche’s MabThera/Rituxan (rituximab), a chimeric monoclonal antibody are currently under development.

Rituximab Safe for Up to 11 Years in Rheumatoid Arthritis

An analysis of data for nearly 3000 patients with RA treated with rituximab for up to 11 years showed no increased risk for serious infection cardiac events or malignancy. Medscape Medical News

Matching PubMed Articles

Patent Deployment Strategies and Patent Value in LED Industry.

This study applies two variables in the measurement of company patent deployment strategies: patent family depth and earn plan ratio. Patent family depth represents the degree to which certain fields ...

Patent Highlights.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Patent Highlights June-July 2015.

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia.

Rituximab in combination with chemotherapy is an effective treatment of patients (pts) with chronic lymphocytic leukemia (CLL). The most frequent adverse event of rituximab is infusion-related toxicit...

Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma.

SUMMARY  Indolent CNS lymphomas (CNSLs) are rare and no guidelines exist for management. Recent literature highlights the potential for safe and tolerable intrathecal (IT) delivery of rituximab, a l...

Search Whole site using Google


Advertisement Advertisement